Tau‐PET‐negative AD patients tended to show higher tau‐PET binding in early regions (ie, MTL) compared to controls, and in late regions compared to only biomarker negative controls, while showing less amyloid burden and less tau accumulation over time than tau‐PET‐positive AD patients in the Amsterdam‐based cohort but similar levels of tau accumulation in ADNI. The gene discussed is MAPT; the disease is amyloidosis.